Cipla announced its Q2 FY26 results, reporting record quarterly revenue of INR 7,589 Cr with a robust EBITDA margin of 25%. The One-India business grew by 7% YoY, while North America delivered $233 Mn in revenue. The company maintains a strong net cash position of INR 9,901 Cr. Cipla’s R&D investment stood at INR 539 Cr, or 7.1% of sales.
Financial Performance Highlights
Cipla reported a record quarterly revenue of INR 7,589 Cr for Q2 FY26, representing an 8% YoY growth. The company achieved an EBITDA of INR 1,895 Cr with a margin of 25%, and a Profit After Tax (PAT) of INR 1,351 Cr, which is an 18% YoY increase.
Segment Performance
The One-India business showed a 7% YoY growth in Q2 FY26. The overall chronic mix improved to 61.8%. Revenue from North America reached $233 Mn, supported by traction in differentiated assets. One Africa continued its growth trajectory with a 5% YoY increase in USD terms. Emerging Markets and Europe posted a solid revenue growth of 15% YoY in USD terms.
R&D and Financial Position
Cipla’s investment in Research and Development (R&D) for the quarter was INR 539 Cr, equivalent to 7.1% of sales, which was driven by product filings and other developmental efforts. The company reported a strong net cash position of INR 9,901 Cr.
Key Strategic Developments
Cipla launched Yurpeak® (Tirzepatide) through a strategic partnership with Eli Lilly, marking a pivotal step into obesity care. The company also anticipates a small contribution to US revenue from gRevlimid in Q3 FY26.
Business Outlook
Cipla remains focused on growing its key markets, further building its flagship brands, and investing in its future pipeline. The company is also committed to resolving regulatory matters.
Source: BSE
